Please ensure Javascript is enabled for purposes of website accessibility

Why Moderna Stock Rose Today

By Joe Tenebruso – Sep 9, 2020 at 6:18PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The coronavirus vaccine race remains wide open.

What happened

Shares of Moderna (MRNA -0.23%) climbed 4.7% on Wednesday after a rival drugmaker's COVID-19 vaccine trial was placed on hold due to safety concerns.

So what

AstraZeneca (AZN 0.08%) paused its phase 3 clinical trial for its coronavirus vaccine candidate, labeled AZD1222, after a participant suffered an unexplained illness. An independent committee will review the safety data before the trial is allowed to resume. "We will be guided by this committee as to when the trials could restart, so that we can continue our work at the earliest opportunity to provide this vaccine broadly, equitably, and at no profit during this pandemic," AstraZeneca CEO Pascal Soriot said in a press release. 

A person is pointing to a chart that rises, then falls, then rises again.

Moderna's stock rallied on Wednesday. Image source: Getty Images.

Although AstraZeneca noted that a pause of this nature is a rather common occurrence during clinical trials, investors took the news as a sign that Moderna may not be as far behind its larger rival as some feared.

Now what 

While being first to market would certainly have its advantages, the outcome of the race for a coronavirus vaccine will ultimately be determined by which drug proves most effective at preventing COVID-19 with the fewest number of negative side effects. It's far too soon to call a winner in that regard -- and Moderna is certainly still in the running.

Joe Tenebruso has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna Inc. Stock Quote
Moderna Inc.
$176.40 (-0.23%) $0.41
AstraZeneca PLC Stock Quote
AstraZeneca PLC
$66.17 (0.08%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.